Aclaris Therapeutics, Inc. (ACRS)
(Delayed Data from NSDQ)
$21.22 USD
+0.55 (2.66%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
4-Sell of 5 4
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value B Growth B Momentum D VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).
ALXNNegative Net Change LXRXNegative Net Change ACRSPositive Net Change BHVNNegative Net Change GRTSNegative Net Change
biotechs pharmaceuticals
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
by Zacks Equity Research
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
UTHRNegative Net Change BLRXNegative Net Change INFINegative Net Change ACRSPositive Net Change
medical
Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.
ACRSPositive Net Change
medical
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ACRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.
PFEPositive Net Change BLRXNegative Net Change AERINegative Net Change ACRSPositive Net Change
pharmaceuticals
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 13.79% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ACRSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACRSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Aclaris (ACRS) Begins Phase II Study on Eczema Candidate
by Zacks Equity Research
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.
ACRXNegative Net Change ABBVNegative Net Change ACRSPositive Net Change AMRXNegative Net Change
pharmaceuticals
Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.
IRWDNegative Net Change JAZZNegative Net Change ONTXNegative Net Change ACRSPositive Net Change
medical
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ACRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ACRSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACRSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
by Zacks Equity Research
Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
BLRXNegative Net Change ACRSPositive Net Change
medical
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
by Zacks Equity Research
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
RIGLNegative Net Change ALDXNegative Net Change ACRSPositive Net Change ATXINegative Net Change
pharmaceuticals
Will Aclaris Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Aclaris Therapeutics
ACRSPositive Net Change
pharmaceuticals
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ACRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACRSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Aclaris (ACRS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
by Zacks Equity Research
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
AGNPositive Net Change RIGLNegative Net Change ACRSPositive Net Change KPTINegative Net Change
medical
Aclaris (ACRS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
by Zacks Equity Research
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
RDHLNegative Net Change ACRSPositive Net Change JAZZNegative Net Change RIGLNegative Net Change
medical
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACRSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Company News for Oct 17, 2019
by Zacks Equity Research
Companies In The News Are: GM, ACRS, MGM, AVD
MGMNegative Net Change GMNegative Net Change AVDNegative Net Change ACRSPositive Net Change
auto-tires-trucks medical
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
by Zacks Equity Research
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
AGNPositive Net Change DERMNegative Net Change RIGLNegative Net Change ACRSPositive Net Change
pharmaceuticals